Supplemental Table S3 from ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

Supplemental Table S3. Summary of siRNA follow-up studies. siRNAs were evaluated in the context of a camptothecin dose response. The primary screen rank is listed for each gene along with the number of siRNAs yielding a 2-fold or greater sensitization. All genes were tested with at least 4 siRNAs from Qiagen (Q). Many genes were characterized with 3 additional siRNAs from Ambion (A). The percent of tested siRNAs yielding a 2-fold or greater sensitization is listed for each gene.补充表S3：siRNA后续研究汇总。本研究以喜树碱（camptothecin）剂量反应为实验背景对小干扰RNA（siRNA）进行评估。文中列出了每种基因的初筛排名，以及可产生2倍及以上增敏效应的siRNA数量。所有基因均使用凯杰公司（Qiagen，Q）提供的至少4条siRNA完成测试；多数基因还额外采用安必昂公司（Ambion，A）提供的另外3条siRNA进行了表征分析。每种基因的可产生2倍及以上增敏效应的测试siRNA占比均已列明。